Low Dose ARD-501 + High Dose ARD-501 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Aug 1, 2024 → Jan 13, 2025
NCT ID
NCT06126653About Low Dose ARD-501 + High Dose ARD-501 + Placebo
Low Dose ARD-501 + High Dose ARD-501 + Placebo is a phase 2 stage product being developed by Aardvark Therapeutics for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT06126653. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06126653 | Phase 2 | Completed |
Competing Products
20 competing products in Autism Spectrum Disorder